Should I buy Arcus Biosciences, Inc. (RCUS) stock or is it too late?
⭐ The most reliable of them, either direction: HC Wainwright & Co. — 61% of its targets hit on this sector (321 calls tested). It aims for $45 (+47 %), call made on July 21, 2026, maturing on July 21, 2027 (38 d ago).
Firm-by-firm track record on Arcus Biosciences, Inc.
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Morgan Stanley | 57 % | +55.2 % | 7 | $22 -28% |
| Barclays | 43 % | +24.3 % | 7 | $14 -54% |
| Mizuho | 33 % | +5.1 % | 6 | $42 +37% |
| Cantor Fitzgerald | 25 % | +0.7 % | 8 | $36 +18% |
| Citigroup | 11 % | -24.8 % | 9 | $45 +47% |
| Wedbush | 0 % | -27.5 % | 8 | $43 +41% |
| SVB Leerink | 40 % | -4.2 % | 10 | — |
✅ Reasons to believe
- 75% of analysts rate it a buy (Buy consensus, 8 ratings) — a sign of market conviction.
- Median price target $44, i.e. +44% from the current price ($31).
⚠️ Reasons to hesitate
- Even the most reliable firm on RCUS, Wells Fargo (67% hit rate, 3 scored calls), only targets $26 (call made on August 6, 2026, maturing on August 6, 2027) (-15%) in its most recent call, and $29 (call made on October 20, 2025, maturing on October 20, 2026) (-5%) in the one coming due soonest. The stock may already have run past its target.
- The consensus is not unanimous: of 8 ratings, 2 are neutral.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
The analyst consensus on RCUS
Median target $44 (+44%) · 8 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Arcus Biosciences, Inc. now?
We won't decide for you. The facts: 75% of analysts rate it a buy, median target $44 (+44%), and Wells Fargo (most reliable on RCUS, 67%) targets $26. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in Arcus Biosciences, Inc.?
Not according to analysts: the median target ($44) is still +44% above the current price ($31) (most reliable on RCUS: Wells Fargo, 67%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Arcus Biosciences, Inc. still worth investing in?
It depends on the gap between the price ($31) and its estimated value: analysts target $44 on median (+44%), with 75% buys (most reliable on RCUS: Wells Fargo, 67%). Cross-check with their real reliability on RCUS and the cautions above. Information, not advice.
What's the main risk in buying RCUS?
Even the most reliable firm on RCUS, Wells Fargo (67% hit rate, 3 scored calls), only targets $26 (call made on August 6, 2026, maturing on August 6, 2027) (-15%) in its most recent call, and $29 (call made on October 20, 2025, maturing on October 20, 2026) (-5%) in the one coming due soonest. The stock may already have run past its target.
→ Go deeper: the full Arcus Biosciences, Inc. profile (consensus, analyst reliability, price target, performance).